|
|
Home > Public Policy and Policy Research > Technology Policy > Access to Drug Labels Survey Report
Access to Drug Labels Survey ReportSummary: The Access to Drug Labels Survey explored the personal stories of people who had trouble reading prescription or over-the-counter medication information. Approximately 100 individuals completed the online survey and, in nearly every instance, respondents explained serious negative consequences of unreadable drug labeling information including illness, emergency room visits, hospitalization, additional expense, and increased anxiety. Introduction According to the 2006 National Health Interview Survey (NHIS)1, approximately 21.2 million Americans reported that they have difficulty seeing, even when wearing eyeglasses or contact lenses, or that they are blind or unable to see at all. For many of these more than 20 million Americans with vision loss, reading drug container labels, such as those on prescription medications, and package inserts about the medication is difficult, or even impossible. Given that the incidence of vision loss is expected to continue to dramatically increase, this poses a significant public health challenge. The American Foundation for the Blind (AFB) has launched Rx Label Enable, a campaign to improve access to drug labeling information for people with vision loss. The campaign aims to ensure that people with vision loss have access to the vital information available to all consumers via prescription labeling and related documentation, enabling them to take medications safely, effectively, and independently. To achieve this goal, AFB is reaching out to consumers experiencing vision loss, policymakers, federal regulators, doctors, the pharmaceutical industry, retailers, assistive technology providers, and public and private insurers to promote solutions, build consensus and take action. The Access to Drug Labels Survey was one component of the Rx Label Enable campaign. Methodology The Access to Drug Labels Survey explored the personal stories of people who had trouble reading prescription or over-the-counter medication information. Respondents voluntarily completed the online questionnaire. This informal online questionnaire consisted of four open ended questions that asked about the extent of vision loss, descriptions of why drug labeling information was unreadable, negative consequences of the unreadable drug information, and strategies or techniques that were used to properly identify and take medications. Results Approximately 100 individuals completed the Access to Drug Labels Survey. Respondents included people of all ages with vision loss, people with all degrees of vision loss, people who have vision loss and may have additional disabilities, and family members of people with vision loss as well as professionals with substantial experience and expertise in this area of vision rehabilitation.Data indicated that the inability to access necessary instructions supplied with prescription and over-the-counter medications often resulted in people with vision loss not taking a proper dose of necessary medication. People with vision loss frequently reported that they have mistakenly taken expired medications or incorrect doses of medication because they were unable to see the expiration dates or dosage information. People with vision loss also reported that they have taken incorrect medication because they were unable to visually tell the difference between medicine containers. In some instances, people with vision loss explained that they were victims of pharmacy errors due to the fact that they could not read the prescription numbers to verify they were given the correct medicine. In other instances, people with vision loss were unable to read the refill instructions. They did not know it was necessary to refill their prescriptions nor did they know the drug number necessary to refill. Nearly every one of the approximately 100 respondents explained that they were dependent either on trusted sighted companions or complete strangers to convey necessary drug information. Respondents consistently reported serious negative consequences of the unreadable drug labeling information including illness, emergency room or hospital visits, additional expense, and increased anxiety. Many of the personal stories respondents shared are provided to further emphasize the critical situation.
In summary, data indicated that the inability to read medication labels and instructions has resulted in serious negative consequences for people with vision loss. The most commonly reported negative consequences of unreadable drug labeling information included:
The fourth and final item on the survey asked respondents to share strategies or techniques used by people with vision loss to properly identify and take medications. The suggestions included strategies such as tactually labeling medicine bottles, differentiating between medicines by their smell, size, texture, or shape as well as asking for sighted assistance. The obvious shortcoming of identifying medication by pill texture, shape, or size clues, for example, was a great matter of concern discussed by many of the participants. Assistive technology devices that use smart-label and speech synthesis technologies to verbalize prescription information can enable people with vision loss to more effectively identify and take medications. There were only a few respondents who addressed the use of these assistive technology devices. The use of this sort of assistive technology can allow those who cannot read their prescription labels, a better way to manage their own medication. Nearly all those who addressed the use of such assistive technology devices explained that these devices were not affordable. Another trend in the response to this fourth and final item was that people who experienced the challenge of vision loss also often experienced the challenge of other disabilities in addition to their vision loss. The presence of additional disabilities can further limit the ability of people with vision loss to effectively manage their medications while also increasing the need for more types of medication. This complicated their ability to devise effective strategies or techniques for properly identifying and taking medications. Discussion Overall results from this informal online questionnaire demonstrated that people with vision loss find themselves unable to take prescription and over-the-counter medicines safely, effectively, and independently due to inaccessible printed drug labeling information. Open ended questions gave respondents the opportunity to share their personal stories. Data indicated that the inability to access necessary instructions supplied with prescription and over-the-counter medicines often resulted in people with vision loss not taking a proper dose of necessary medication. In nearly every instance, respondents explained the serious negative consequences of unreadable drug labeling information and that they were dependent either on trusted sighted companions or complete strangers to convey necessary drug information. There were only a few personal stories that addressed the use of assistive technology devices that can allow those who cannot read their prescription labels, a better way to manage their own medication. The few respondents who did address the use of such assistive technology devices explained that these devices were not affordable. The findings of this survey indicated that the lack of awareness and affordability were two substantial barriers people with vision loss experienced in accessing these high-tech devices. No single currently available assistive technology or modality can meet the needs of all of the growing population of people with vision loss. This population of people with vision loss is not homogenous and, therefore, multiple means of communicating drug information are necessary. Increasing age, additional disabilities, socioeconomic status, severity of vision loss, and skill in the use of computer and/or assistive technologies should be taken into consideration when researching or developing assistive technologies or modalities for use by people with vision loss to access prescription drug information. Thus, assistive technology devices that use smart-label and speech synthesis technologies to verbalize prescription information seem to have not yet reached their full potential. To be most effective, an assistive technology or modality that allows those with vision loss a better way to manage their own medication should have certain features. The assistive technology device should:
Policy Implications Even though people of all ages with all degrees of vision loss are affected by the negative consequences of inaccessible drug labeling information, there are essentially no federal guidelines for pharmacists to follow in making prescription labels accessible. The Food and Drug Administration (FDA) implements laws and regulations that govern prescription drug information. However, the FDA has never issued specific regulations or guidelines to guarantee that prescription drug information intended for patients is accessible for people with vision loss. In general, states are the primary regulators of the content and format provided directly on a prescription bottle and/or pharmacy-provided packaging. Nearly all of the states in the union have statutory requirements pertaining to prescription labeling. However, no state law ensures that prescription labeling is accessible to persons with vision loss. Even the state of Massachusetts, which attempts to establish such requirements, merely provides: "upon the request of-a person visually impaired [sic], directions on the label affixed by the pharmacist to a container of a prescription drug shall be typed in a print size allowing no more than ten characters per inch (Mass. Gen. Laws Ch. 94C, §21)." Few states have ever considered adopting a clear accessibility requirement-the California legislature is currently considering such a proposal, AB 1399, which provides: "upon the request of a customer who is blind or visually impaired, a pharmacist shall provide a prescription drug label that is readable by an assistive technology device for the blind or visually impaired". Some pharmacies are beginning to experiment with different ways to offer their customers alternate means of identifying prescription medications. However, while such efforts are well-intentioned, they do not amount to a national trend and are not based on any reliable standards or evidence of their effectiveness. Nationally, few pharmacies are voluntarily providing their customers with meaningful access to the labeling and other information related to prescription medications they dispense. Moreover, those pharmacies that have begun to try to provide their customers with vision loss with prescription information they can use are doing so in a vacuum without standards that ensure complete and consistent presentation of information. Recent Actions As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress called upon the FDA to investigate solutions addressing the problem of inaccessible prescription drug labeling. Unfortunately, the report issued to Congress in May 2005 failed to describe specific processes, regulatory changes, or other solutions ensuring access. Nevertheless, the report does affirm that "all Americans, whether visually impaired or not, should have equal access to essential prescription drug information". In essence the FDA missed an opportunity to offer meaningful answers to the challenge of inaccessible labeling and related information. Since the study's release in May 2005, some effort has been made to convene expert panels to begin to formulate questions for future research and the development/communication of stopgap solutions. Even though the Secretary of Health and Human Services, Mike Leavitt, in announcing the introduction of FDA's new packaging insert format requirements, recognized that "clear and concise information about prescriptions will help ensure safe and optimal use of drugs", this language is limited only to package inserts and fails to consider accessibility for people with disabilities. Action Needed Now Congress should grant the FDA clear authority to regulate this area and develop standards to ensure that prescription labeling is accessible to individuals with vision loss. A number of existing solutions demonstrate the feasibility of providing access to prescription drug labeling and pharmacies should be prepared to provide prescription labeling in multiple modalities. 1 Data source: National Center for Health Statistics, National Health Interview Survey, 2006, www.cdc.gov/nchs/nhis.htm . For further information, see "Pleis J.R., Lethbridge-Çejku M. (2007). Summary health statistics for U.S. adults: National Health Interview Survey, 2006. National Center for Health Statistics. Vital Health Stat 10 (235)." Prepared December 2008 For further information, contact Stacy Kelly, Policy Research Associate |
|
||||||||
|
Printer-Friendly Format |
||||||||||
Help expand possibilities for people with vision loss—Donate to AFB. |
|
| Having trouble reading the site? Check out the American
Foundation for the Blind's accessibility options. You can change the colors
on our site, increase the text size, and even change the font to something you find more readable.
Screen reader users can move repetitive links out of their way, by pushing the navigation bar to the
bottom of the page. |
|
| AFB would like to hear from you. Please contact us with your comments and suggestions. Link to Us | Site Map | Policy Statement | Copyright © 2010 American Foundation for the Blind. All rights reserved. Material provided on AFB.org is intended for information use only and is not a substitute for professional medical advice. If you have any concerns about your health, please contact your health provider. |
|